Haemonetics Corp(HAE) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | RUT | P/E | 49.29 | EPS (ttm) | 2.05 | Insider Own | 1.88% | Shs Outstand | 45.5M | Perf Week | -1.81% |
| Market Cap | 4.60B | Forward P/E | 17.61 | EPS next Y | 8.35% | Insider Trans | - | Shs Float | 44.6M | Perf Month | 15.87% |
| Enterprise Value | 5.55B | PEG | 2.03 | EPS next Q | 1.29 | Inst Own | 115.07% | Short Float | 6.19% | Perf Quarter | 28.25% |
| Income | 0.10B | P/S | 3.4 | EPS this Y | 6.79% | Inst Trans | 3.46% | Short Ratio | 3.48 | Perf Half Y | 66.71% |
| Sales | 1.35B | P/B | 5.49 | EPS next 5Y | 8.66% | ROA | 3.99% | Short Interest | 2.76M | Perf YTD | 26.09% |
| Book/sh | 18.41 | P/C | 20.58 | EPS past 3/5Y | -2.9% 5.81% | ROE | 11.2% | 52W High | -7.77% ($109.57) | Perf Year | 88.3% |
| Cash/sh | 4.91 | P/FCF | 15.79 | Sales past 3/5Y | 4.51% 8.91% | ROIC | 4.8% | 52W Low | 113.59% ($47.31) | Perf 3Y | 14.22% |
| Dividend Est. | $1 (0.99%) | EV/EBITDA | 15.48 | EPS Y/Y TTM | -37.48% | Gross Margin | 55.91% | Volatility(W/M) | 2.37% 2.67% | Perf 5Y | 49.79% |
| Dividend TTM | - | EV/Sales | 4.1 | Sales Y/Y TTM | 0.44% | Oper. Margin | 18.37% | ATR (14) | 2.88 | Perf 10Y | 179.33% |
| Dividend Ex-Date | - | Quick Ratio | 1.91 | EPS Q/Q | 2.63% | Profit Margin | 7.12% | RSI (14) | 58.06 | Recom | 1.83 |
| Dividend Gr. 3/5Y | - | Current Ratio | 3.08 | Sales Q/Q | 5.6% | SMA20 | -1.62% ($102.72) | Beta | 0.61 | Target Price | $108.4 |
| Payout | - | Debt/Eq | 1.4 | Earnings | 2026/8/6 | SMA50 | 13.14% ($89.32) | Rel Volume | 0.76 | Prev Close | $103.16 |
| Employees | 3009 | LT Debt/Eq | 1.4 | EPS/Sales Surpr. | 5.87% 3.51% | SMA200 | 38.24% ($73.1) | Avg Volume(3M) | 0.79M | Price | $101.06 |
| IPO | 1991/5/10 | Option/Short | Yes/Yes | Trades | 7939 | Volume | 602,320 | Change | -2.04% |
Company
HAE is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.
A US medical device company that supplies blood and plasma management medical devices. It provides plasma collection systems, hospital hemostasis and blood management solutions, and blood center equipment, with exposure to plasma demand and hospital adoption. A company in the blood and plasma management field.
Over the past 1 year, on the higher side
8% below its 1-year high.
HAE makes money exceptionally well
18.37% of revenue is kept as operating profit.
Tap to view numbers
Growth is moderate
Earnings are expected to grow by +6.8% this year.
Tap to view numbers
The price looks about right
Trading at 49.3 times earnings.
Tap to view numbers
It has beaten expectations every time
Beat market estimates in the last 3 quarters.
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Buy.
Tap to view numbers
Holding long would have paid off
Would have changed by +14.2% if bought 5 years ago.
Tap to view numbers
The dividend is on the small side
Pays 0.99% annually in dividends.
Tap to view numbers
Ownership looks stable
Institutions hold 115.1%.
Tap to view numbers
Multiple ETFs hold this stock
Buying this ETF gives you exposure to this stock as well.
NBSM 0.02%
BTR 0.02%
FFLS 0.02%
XHE 0.02%
ACVT 0.01%It ranks #4 in the industry
Based on market cap of $5B.
HAE $5B PER 49.3
ABT $179B PER 33.4
MDT $117B PER 22.6
SYK $104B PER 28.0
FAQ
What kind of company is HAE?
HAE belongs to the Healthcare sector and operates in the Medical Devices industry.
What is the market cap of HAE?
The market cap of HAE is approximately $4.6B, ranking 1,447 within its sector.
Does HAE pay dividends?
HAE has a dividend yield of approximately 0.99%, with an annual dividend of $1.00.
What is the P/E ratio of HAE?
HAE has a P/E ratio of approximately 49.3x, which can be used to assess its valuation relative to the Healthcare sector average.
What is the 52-week high and low for HAE?
HAE has recorded a 52-week high of $109.57 and a low of $47.31.
